Milan, Italy Mar. 14, 2022
KLISBio to share innovative tissue-engineered technology at LSI 2022 Emerging MedTech Summit
Milan, Italy (March 14, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to LSI 2022 Emerging MedTech Summit. LSI Annual Meeting will be held March 15 -18, 2022 in Dana Point – CA. KLISBio’s designated attendee to LSI Emerging MedTech Summit is Jason Schense, CBO and COO.
Among the most innovative MedTech emerging companies, KLISBio is keen to deal-make and establish strong relations with active investors and paramount players in the life science and regenerative medicine space, aiming to contribute to the advancement of the whole industry with SILKBridge®, KLISBio’s first product in pipeline for peripheral nerve repair.
SILKBridge® is an absorbable medical device made of Bombyx mori silk fibroin and is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. SILKBridge® is expected to be available for clinical use in the US market in 2023. The tissue engineered technology at the core of SILKBridge® merges a deep-rooted cultural tradition and know-how with the most advanced technologies creating a highly purified material required for biomedical applications, without the need for chemical cross-linking reactions that alter silk fibroin.
“KLISBio is focused on developing innovative solutions to tackle prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed.”, said Jason Schense, CBO and COO at KLISBio.
KLISBio is powered by an international group of world leaders in MedTech including Grecchi, CEO; Antonio Alessandrino, President & Chief Technology Officer; Giuliano Freddi, Chief Scientific Officer; Jason Schense, Chief Business Officer and Chief Operating Officer. The company recently announced that Rodrigo Bianchi will serve as Chairman of the Board, coming to KLISBio with more than three decades’ experience in global healthcare.
In addition to the strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space. The company holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers.
KLISBio is a clinical-stage regenerative medicine company focused on developing innovative technology platforms entirely based on natural silk fibroin. The company, headquatered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes and rotator cuff repair.